Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Objectives: This four-armed phase III trial asks whether carboplatin can make tumor cell more sensitive to radiotherapy and whether isoretinoin can make them more sensitive to chemotherapy drugs. It compares a regimen that adds carboplatin to standard chemoradiotherapy with standard chemoradiotherapy alone. Patients are also randomized to standard maintenance therapy alone or standard maintenance therapy plus isotretinoin and continuation therapy with isotretinoin.

Key entry or exclusion criteria: Patients, ages 3-21 years, must have undergone stereotactic biopsy or attempted neurosurgical resection of the tumor within the past 31 days.

Locations: 160 sites

Goal: 300 patients

Study sponsor: Children’s Oncology Group in collaboration with the National Cancer Institute

Link for more information: clinicaltrials.gov/ct2/results?term=NCT00392327

NIH clinical trials identifier: NCT00392327

Objectives: This four-armed phase III trial asks whether carboplatin can make tumor cell more sensitive to radiotherapy and whether isoretinoin can make them more sensitive to chemotherapy drugs. It compares a regimen that adds carboplatin to standard chemoradiotherapy with standard chemoradiotherapy alone. Patients are also randomized to standard maintenance therapy alone or standard maintenance therapy plus isotretinoin and continuation therapy with isotretinoin.

Key entry or exclusion criteria: Patients, ages 3-21 years, must have undergone stereotactic biopsy or attempted neurosurgical resection of the tumor within the past 31 days.

Locations: 160 sites

Goal: 300 patients

Study sponsor: Children’s Oncology Group in collaboration with the National Cancer Institute

Link for more information: clinicaltrials.gov/ct2/results?term=NCT00392327

NIH clinical trials identifier: NCT00392327

Objectives: This four-armed phase III trial asks whether carboplatin can make tumor cell more sensitive to radiotherapy and whether isoretinoin can make them more sensitive to chemotherapy drugs. It compares a regimen that adds carboplatin to standard chemoradiotherapy with standard chemoradiotherapy alone. Patients are also randomized to standard maintenance therapy alone or standard maintenance therapy plus isotretinoin and continuation therapy with isotretinoin.

Key entry or exclusion criteria: Patients, ages 3-21 years, must have undergone stereotactic biopsy or attempted neurosurgical resection of the tumor within the past 31 days.

Locations: 160 sites

Goal: 300 patients

Study sponsor: Children’s Oncology Group in collaboration with the National Cancer Institute

Link for more information: clinicaltrials.gov/ct2/results?term=NCT00392327

NIH clinical trials identifier: NCT00392327